CC BY-NC-ND 4.0 · Endoscopy 2023; 55(04): 344-352
DOI: 10.1055/a-1945-9120
Original article
Hideki Ishikawa 1 Department of Molecular-Targeting Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan , 2 Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan , Yasushi Sato 3 Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Hokkaido, Japan , 4 Endoscopy and Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan , Chino Akiko 5 Department of Gastroenterology, Cancer Institute Hospital, Tokyo, Japan , 6 Department of Endoscopy, Aichi Cancer Center Hospital, Aichi, Japan , Hisashi Doyama 7 Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan , Tetsuji Takayama 8 Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan , Yoshio Ohda 9 Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan , Takahiro Horimatsu 10 Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan , 11 Sano Hospital, Hyogo, Japan
,
Kohji Tanakaya
12 Department of Surgery, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan
,
Hiroaki Ikematsu
13 Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan
,
Yoshihisa Saida
14 Department of Surgery, Toho University Ohashi Medical Center, Tokyo, Japan
,
Hideyuki Ishida
15 Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
,
16 Department of Gastrointestinal Oncology, Osaka International Cancer Institute (formerly Osaka Medical Center for Cancer and Cardiovascular Diseases), Osaka, Japan
,
Hiroshi Kashida
17 Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan
,
Shinsuke Kiriyama
18 Department of Surgery, Gunma Chuo Hospital, Gunma, Japan
,
Shinichiro Hori
19 Department of Internal Medicine, National Hospital Organization Shikoku Cancer Center, Ehime, Japan
,
Kyowon Lee
20 Moriguchi Keijinkai Hospital, Osaka, Japan
,
Jun Tashiro
21 Department of Gastroenterology, Toshiba Hospital, Tokyo, Japan
,
Nozomu Kobayashi
22 Department of Gastroenterology, Tochigi Cancer Center, Tochigi, Japan
,
Takeshi Nakajima
2 Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan
,
Sadao Suzuki
23 Department of Public Health, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan
,
Michihiro Mutoh
1 Department of Molecular-Targeting Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan
24 Epidemiology and Prevention Group, Research Center for Cancer Prevention and Screening/Center for Public Health Sciences, National Cancer Center, Tokyo, Japan
,
› Further Information
Permissions and Reprints
Referred to by:
Is there a role for endoscopic management of the large bowel in familial adenomatous polyposis?Endoscopy 2023; 55(04): 353-354
DOI: 10.1055/a-1990-1046
Referred to by:
Author commentary on Hideki Ishikawa et al.Endoscopy 2023; 55(04): v10-v10
DOI: 10.1055/a-1956-7292
Abstract
Background Total colectomy is the standard treatment for familial adenomatous polyposis (FAP). Recently, an increasing number of young patients with FAP have requested the postponement of surgery or have refused to undergo surgery. We aimed to evaluate the effectiveness of intensive endoscopic removal for downstaging of polyp burden (IDP) in FAP.
Method A single-arm intervention study was conducted at 22 facilities. Participants were patients with FAP, aged ≥ 16 years, who had not undergone colectomy or who had undergone colectomy but had ≥ 10 cm of large intestine remaining. For IDP, colorectal polyps of ≥ 10 mm were removed, followed by polyps of ≥ 5 mm. The primary end point was the presence/absence of colectomy during a 5-year intervention period.
Results 222 patients were eligible, of whom 166 had not undergone colectomy, 46 had undergone subtotal colectomy with ileorectal anastomosis, and 10 had undergone partial resection of the large intestine. During the intervention period, five patients (2.3 %, 95 % confidence interval [CI] 0.74 %–5.18 %) underwent colectomy, and three patients died. Completion of the 5-year intervention period without colectomy was confirmed in 150 /166 patients who had not undergone colectomy (90.4 %, 95 %CI 84.8 %–94.4 %) and in 47 /56 patients who had previously undergone colectomy (83.9 %, 95 %CI 71.7 %–92.4 %).
Conclusion IDP in patients with mild-to-moderate FAP could have the potential to be a useful means of preventing colorectal cancer without implementing colectomy. However, if the IDP protocol was proposed during a much longer term, it may not preclude the possibility that a large proportion of colectomies may still need to be performed.
Supplementary material
- Supplementary material
Publication History
Received: 24 April 2022
Accepted after revision: 24 August 2022
Article published online:
10 October 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
References
- 1 Iwama T, Tamura K, Morita T. et al. A clinical overview of familial adenomatous polyposis derived from the database of the polyposis registry of Japan. Int J Clin Oncol 2004; 9: 308-316
- 2 Vasen HF, Möslein G, Alonso A. et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57: 704-713
- 3 Smith AJ, Lewis JJ, Merchant NB. et al. Surgical management of intra-abdominal desmoid tumours. Br J Surg 2000; 87: 608-613
- 4 Nielsen M, Hes FJ, Nagengast FM. et al. Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. Clin Genet 2007; 71: 427-433
- 5 Tomita N, Ishida H, Tanakaya K. et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines: 2020 for the Clinical Practice of Hereditary Colorectal Cancer. Int J Clin Oncol 2021; 26; 1353-1419
- 6 Koskenvuo L, Renkonen-Sinisalo L, Jarvinen HJ. et al. Risk of cancer and secondary proctectomy after colectomy and ileorectal anastomosis in familial adenomatous polyposis. Int J Colorectal Dis 2014; 29: 225-230
- 7 Campos FG, Perez RO, Imperiale AR. et al. Surgical treatment of familial adenomatous polyposis: ileorectal anastomosis or restorative proctolectomy?. Arq Gastroenterol 2009; 46: 294-299
- 8 Winawer SJ, Zauber AG, Ho MN. et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-1981
- 9 Vogelstein B, Fearon ER, Hamilton SR. et al. Genetic alterations during colorectal-tumor development. New Engl J Med 1988; 319: 525-532
- 10 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 2000; 61: 759-767
- 11 Pasquer A, Benech N, Pioche M. et al. Prophylactic colectomy and rectal preservation in FAP: systematic endoscopic follow-up and adenoma destruction changes natural history of polyposis. Endosc Int Open 2021; 9: E1014-E1022
Article in Thieme ConnectPubMedGoogle Scholar
- 12 Ishikawa H, Mutoh M, Iwama T. et al. Endoscopic management of familial adenomatous polyposis in patients refusing colectomy. Endoscopy 2016; 48: 51-55
- 13 Tokudome S, Goto C, Imaeda N. et al. Development of a data-based short food frequency questionnaire for assessing nutrient intake by middle-aged Japanese. Asian Pacific J Cancer Prev 2004; 5: 40-43
PubMedGoogle Scholar
- 14 Ishikawa H, Mutoh M, Sato Y. et al. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial. Lancet Gastroenterol Hepatol 2021; 6: 474-481
- 15 Campos FG. Surgical treatment of familial adenomatous polyposis: dilemmas and current recommendations. World J Gastroenterol 2014; 20: 16620-16629
- 16 Sinha A, Burns EM, Latchford A. et al. Risk of desmoid formation after laparoscopic versus open colectomy and ileorectal anastomosis for familial adenomatous polyposis. BJS Open 2018; 2: 452-455
- 17 Chittleborough TJ, Warrier SK, Heriot AG. et al. Dispelling misconceptions in the management of familial adenomatous polyposis. ANZ J Surg 2017; 87: 441-445
- 18 Lynch PM, Morris JS, Wen S. et al. A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointest Endosc 2016; 84: 115-25.e4
- 19 Septer S, Lawson CE, Anant S. et al. Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate. Fam Cancer 2016; 15: 477-485
- Supplementary Material
- Supplementary material